Safety of factor XI inhibition with abelacimab in atrial fibrillation by kidney function

JAMA Cardiology

2025-09-01

(Press-News.org) About The Study: In this secondary analysis of the AZALEA-TIMI 71 randomized clinical trial, abelacimab consistently reduced the risk of bleeding relative to rivaroxaban irrespective of kidney function. These findings suggest that abelacimab may offer a particularly favorable safety profile among those with chronic kidney disease; however, larger studies are necessary to characterize the efficacy of abelacimab for stroke prevention in atrial fibrillation.

Corresponding Author: To contact the corresponding author, Siddharth M. Patel, MD, MPH, email spatel@bwh.harvard.edu.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2025.3393?guestAccessKey=0e6929b9-90af-492b-991f-52f316b6dfb9&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=090125

END

ELSE PRESS RELEASES FROM THIS DATE:

Combination of mini-camera and AI predicts recurrent heart attack

2025-09-01

Measurements with a miniature camera inside the coronary arteries can accurately predict whether someone will suffer a recurrent heart attack. Until now, interpreting these images was so complex that only specialized laboratories could perform it. A new study from Radboud university medical center shows that AI can reliably take over this analysis and rapidly assess arteries for weak spots. A heart attack occurs when a coronary artery, which supplies the heart with blood, is blocked by a blood clot. This can occur when atherosclerosis causes artery narrowing, resulting in the heart receiving too little oxygen. Treatment typically ...

Study Reveals Details of Overactive Immune System in Patients with Chronic Fatigue Syndrome (ME/CFS)

2025-09-01

Patients with chronic fatigue syndrome/myalgic encephalomyelitis (ME/CFS) have heightened innate immune responses to bacteria, viruses and fungi. While these responses are essential to fight infection, they can cause damage when unchecked. Led by researchers at the Center for Infection and Immunity (CII) at Columbia University Mailman School of Public Health with a multicenter team of leading ME/CFS researchers, the new study reveals molecular-level details into the syndrome’s lasting effects on inflammation and immune response that could inform the development of targeted therapeutic interventions to ...

UTSA and UT Health San Antonio complete merger to become The University of Texas at San Antonio

2025-09-01

SAN ANTONIO, Sept. 1, 2025 – UTSA and The University of Texas Health Science Center at San Antonio (UT Health San Antonio) today merged to form The University of Texas at San Antonio (UT San Antonio), a premier global university that is deeply committed to making lives better for the communities it serves. As a merged institution, UT San Antonio now ranks as the third-largest public research university in Texas according to annual research expenditures, behind only Texas A&M University and the University of Texas at Austin. UT San Antonio’s comprehensive enterprise now includes approximately 40,000 students, 17,000 employees and more than $486 million in annual ...

Helicobacter pylori screening after acute myocardial infarction

2025-09-01

About The Study: Among unselected patients with acute myocardial infarction, routine H pylori screening did not significantly reduce the risk of upper gastrointestinal bleeding. Corresponding Author: To contact the corresponding author, Robin Hofmann, MD, PhD, email robin.hofmann@ki.se. To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support. Embed this link to provide your readers ...

Solar Orbiter traces superfast electrons back to Sun

2025-09-01

The European Space Agency-led Solar Orbiter mission has split the flood of energetic particles flung out into space from the Sun into two groups, tracing each back to a different kind of outburst from our star. The Sun is the most energetic particle accelerator in the Solar System. It whips up electrons to nearly the speed of light and flings them out into space, flooding the Solar System with so-called ‘Solar Energetic Electrons’ (SEEs). Researchers have now used Solar Orbiter to pinpoint the source of these energetic electrons and trace what we see out in space back to what’s actually ...

GaN-based electron beam technology from Nagoya University startup poised to overcome critical semiconductor manufacturing challenges at KIOXIA

2025-09-01

NAGOYA, Japan — In late September 2025, KIOXIA Iwate Corporation (Koichiro Shibayama CEO) will begin evaluating a GaN-based e-beam technology developed through joint research between Photo electron Soul Inc. (PeS; Takayuki Suzuki CEO), a Nagoya University startup, and the Amano–Honda Laboratory at Nagoya University. PeS has developed a next-generation electron gun specialized for GaN (gallium nitride) photocathodes and has demonstrated its effectiveness for semiconductor inspection and metrology (I&M), enabling electron microscopy of nanoscale transistors and high-aspect-ratio structures. These ...

Circle versus rectangle: Finding ‘Earth 2.0’ may be easier using a new telescope shape

2025-09-01

by Prof Heidi Newberg The Earth supports the only known life in the universe, all of it depending heavily on the presence of liquid water to facilitate chemical reactions. While single-celled life has existed almost as long as the Earth itself, it took roughly three billion years for multicellular life to form. Human life has existed for less than one 10 thousandth of the age of the Earth. All of this suggests that life might be common on planets that support liquid water, but it might be uncommon to find life that studies the universe and seeks to travel ...

Metformin changes blood metal levels in humans

2025-09-01

The widely used diabetes drug metformin changes blood metal levels in humans. The Kobe University study is an important step in understanding the drug’s many actions and designing better ones in the future. Metformin is the most widely prescribed diabetes drug in the world. Apart from lowering blood sugar levels, it is also known to have a broad range of beneficial side effects such as against tumors, inflammations and atherosclerosis. However, although it has been used for more than 60 years ...

Long-term anticoagulation discontinuation after catheter ablation for atrial fibrillation

2025-08-31

About The Study: Among patients without documented atrial arrhythmia recurrence after catheter ablation for atrial fibrillation, discontinuing oral anticoagulant therapy resulted in a lower risk for the composite outcome of stroke, systemic embolism, and major bleeding vs continuing direct oral anticoagulant therapy. Corresponding Author: To contact the corresponding author, Boyoung Joung, MD, email cby6908@yuhs.ac. To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ Editor’s Note: Please see the article for additional information, including other authors, author contributions and ...

Fractional flow reserve–guided complete vs culprit-only revascularization in non–ST-elevation myocardial infarction and multivessel disease

2025-08-31

About The Study: Fractional flow reserve-guided complete revascularization during the index procedure resulted in a significant reduction in the composite of all-cause death, nonfatal myocardial infarction, any revascularization, and stroke at 1 year. This was mainly driven by reduced repeat revascularization. Corresponding Author: To contact the corresponding author, Tobias F. S. Pustjens, MD, email t.pustjens@gmail.com. To access the embargoed study: Visit our For The Media website at this link ...

Safety of factor XI inhibition with abelacimab in atrial fibrillation by kidney function

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: